Forecast came true

Valeant Pharmaceuticals (VRX) Will Go Up After Earnings
3 november

Valeant Pharmaceuticals (VRX) is down on Teva's woes.


But debt reduction, cash flow growth, non-GAAP growth and B+L sales increases will lift the stock price.

VRX STOCK:

$VRX, VALEANT PHARMACEUTICALS INTERNATIONAL / H1

TEVA STOCK:

$TEVA, TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DEPOSITARY SHARES / H1


VRX 2018 PT $15.

Valeant will go up after earnings on November 7 bmo. Agree or disagree?

Vote with your peers - 800 members in the Value Stock Group.

Agree: VRX Up after ER.

Disagree: VRX will fall after earnings.

Answered:
14 people

Valeant Pharmaceuticals (VRX) Will Go Up After Earnings

Agreed
11 people
Disagreed
3 people

Forecast came true

Closed at $15, up from $11.